Literature DB >> 22752252

Measurement of drug in small particles from aqueous nasal sprays by Andersen Cascade Impactor.

William H Doub1, Wallace P Adams, Anna M Wokovich, John C Black, Meiyu Shen, Lucinda F Buhse.   

Abstract

PURPOSE: To determine if cascade impactor (CI) measurement of drug in small particles from aqueous nasal sprays, described in FDA's 2003 draft Nasal Bioavailability/Bioequivalence Guidance, can be optimized to reduce measurement variability. To examine the influence of flow rate configurations and number of impactor stages on CI deposition and explore the importance of inlet volume.
METHODS: A total of eight assemblies and manual vs. automatic actuation were tested for deposition on the sum of all stages of the CI, and for Group 2 total drug mass per the Guidance. Mean deposition and variance about the mean were determined for each assembly.
RESULTS: The path length for a spherical 1 l inlet was too short to allow adequate aerosol formation. Data variance was reduced by a factor of two or more by using an automatic actuator relative to manual actuation. Impactor assembly modification did not improve variance over the standard assembly.
CONCLUSIONS: Use of a spherical inlet (≥ 2 l volume) and automatic actuation are recommended for comparative measurements of drug in small particles arising from aqueous nasal sprays. The standard (8-stage) 28.3 lpm CI flow rate configuration is recommended when using the Andersen Cascade Impactor (ACI), as no other assembly showed a distinct advantage.

Mesh:

Substances:

Year:  2012        PMID: 22752252     DOI: 10.1007/s11095-012-0804-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

Review 1.  Assessing nebulizer performance.

Authors:  Myrna B Dolovich
Journal:  Respir Care       Date:  2002-11       Impact factor: 2.258

2.  Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree.

Authors:  Dave Christopher; Paul Curry; Bill Doub; Kenneth Furnkranz; Martin Lavery; Karl Lin; Svetlana Lyapustina; Jolyon Mitchell; Brian Rogers; Helen Strickland; Terrence Tougas; Yi Tsong; Bruce Wyka
Journal:  J Aerosol Med       Date:  2003

3.  Comparison of cascade impaction and laser diffraction for particle size distribution measurements.

Authors:  Jochen Ziegler; Herbert Wachtel
Journal:  J Aerosol Med       Date:  2005

4.  Calibration of the Andersen cascade impactor for the characterization of nasal products.

Authors:  Robert J Garmise; Anthony J Hickey
Journal:  J Pharm Sci       Date:  2008-08       Impact factor: 3.534

Review 5.  Minimizing variability of cascade impaction measurements in inhalers and nebulizers.

Authors:  Matthew Bonam; David Christopher; David Cipolla; Brent Donovan; David Goodwin; Susan Holmes; Svetlana Lyapustina; Jolyon Mitchell; Steve Nichols; Gunilla Pettersson; Chris Quale; Nagaraja Rao; Dilraj Singh; Terrence Tougas; Mike Van Oort; Bernd Walther; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2008-02-28       Impact factor: 3.246

6.  Deposition pattern of nasal sprays in man.

Authors:  S P Newman; F Morén; S W Clarke
Journal:  Rhinology       Date:  1988-06       Impact factor: 3.681

7.  The distribution of an intranasal insulin formulation in healthy volunteers: effect of different administration techniques.

Authors:  S P Newman; K P Steed; J G Hardy; I R Wilding; G Hooper; R A Sparrow
Journal:  J Pharm Pharmacol       Date:  1994-08       Impact factor: 3.765

8.  Nasal distribution of budesonide inhaled via a powder inhaler.

Authors:  L Thorsson; S P Newman; A Weisz; E Trofast; F Morén
Journal:  Rhinology       Date:  1993-03       Impact factor: 3.681

9.  General high-performance liquid chromatographic procedures for the rapid screening of natural and synthetic corticosteroids.

Authors:  L Valvo; A Paris; A L Savella; B Gallinella; E Ciranni Signoretti
Journal:  J Pharm Biomed Anal       Date:  1994-06       Impact factor: 3.935

10.  Scintigraphic assessment of the oropharyngeal and nasal depositions of fusafungine from a pressurized inhaler and from a novel pump spray device.

Authors:  S P Newman; K P Steed; G Hooper; J Brickwell
Journal:  J Pharm Pharmacol       Date:  1995-10       Impact factor: 3.765

View more
  2 in total

1.  A Systematic Approach in the Development of the Morphologically-Directed Raman Spectroscopy Methodology for Characterizing Nasal Suspension Drug Products.

Authors:  Gonçalo Farias; Jagdeep Shur; Robert Price; Elizabeth Bielski; Bryan Newman
Journal:  AAPS J       Date:  2021-05-18       Impact factor: 4.009

Review 2.  In Vitro Anatomical Models for Nasal Drug Delivery.

Authors:  Gerallt Williams; Julie D Suman
Journal:  Pharmaceutics       Date:  2022-06-26       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.